Logo
d

dMed Biopharmaceutical Co., Ltd. dba Caidya

172 employees

dMed is Now Caidya! Caidya is a global, multi-therapeutic clinical research organization (CRO) dedicated to advancing healthcare innovation and accelerating the development of new therapies. With full-service capabilities and a strategic footprint in 23 countries and regions, our global network provides broad access to diverse patient populations across the Americas, Europe, and APAC. Caidya’s in-depth therapeutic and operational expertise helps partners conduct studies with greater efficiency and confidence. Our commitment to excellence and data-driven decision-making ensures the highest quality standards across all phases of the drug development process. Caidya provides comprehensive clinical trial services from regulatory strategy and submissions, clinical operations, biometrics, and quality management, through post-approval surveillance. Following the merger of dMed and Clinipace, Caidya launched with a clear purpose to liberate clinical research and bring life-changing therapies to our global community.

Investor insights

Funding rounds participated in

$50M sweet spot round size

Investor type

Privately Held

Basic info

Industry

Pharmaceutical Manufacturing

Sectors

Pharmaceutical Manufacturing

Date founded

2016

Funding rounds raised

Total raised

$50M

from 2 investors over 1 rounds

d

dMed Biopharmaceutical Co., Ltd. dba Caidya raised $50M on August 10, 2021

Investors: SpringHill Management and + 3 Other investors

FAQ